文献速递血液净化与透析肾血管病与高血压

血液透析合并高脂血症患者接受他汀治疗与外周动脉疾病风险增加相关:台湾地区人群队列研究

Increased risk of developing peripheral artery disease in hemodialysis patients receiving statin treatments: a population-based cohort study in Taiwan.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

平均随访4.18年,他汀使用者发生外周动脉疾病的风险是非使用者的1.35倍(16.87 vs 12.46/1000人年),调整后HR为1.34(95%CI 1.12-1.62),且风险随他汀年均剂量增加而升高。结论提示血液透析合并高脂血症患者使用他汀与外周动脉疾病风险增加相关,处方前需全面权衡。

要点

  • 血液透析合并高脂血症患者使用他汀者外周动脉疾病风险显著升高(aHR 1.34,95%CI 1.12-1.62)。
  • 氟伐他汀(aHR 1.88)与阿托伐他汀(aHR 1.60)使用者风险增加显著。
  • 外周动脉疾病风险随他汀年均剂量增加而升高(趋势P<0.0001)。

核心结论

  • 血液透析合并高脂血症患者接受他汀治疗与外周动脉疾病风险增加相关,且风险随累积他汀剂量增加而升高。
  • 处方他汀前需对血液透析患者进行全面考量。

研究设计与样本

  • 基于台湾地区全民健康保险研究数据库的人群队列研究。
  • 采用Cox比例风险回归分析评估外周动脉疾病发生风险。

主要发现

  • 平均随访4.18年,他汀组外周动脉疾病发生风险为非他汀组的1.35倍(16.87 vs 12.46/1000人年),调整后HR为1.34(95%CI 1.12-1.62)。
  • 氟伐他汀使用者外周动脉疾病风险显著增加(aHR 1.88;95%CI 1.12-3.14)。
  • 阿托伐他汀使用者外周动脉疾病风险显著增加(aHR 1.60;95%CI 1.24-2.08)。
  • 外周动脉疾病风险随他汀年均剂量增加而升高(趋势P<0.0001)。
  • 接受中等强度他汀治疗者风险更高;敏感性分析结果类似。

临床怎么用

  • 对血液透析合并高脂血症患者处方他汀时,应充分评估外周动脉疾病风险与获益。
  • 使用他汀的血液透析患者需关注外周动脉疾病相关症状及监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few investigations have evaluated the influences on peripheral arterial disease (PAD) risk of statin treatment in hemodialysis (HD) subjects with hyperlipidemia (HL). METHODS: From the National Health Insurance Research Dataset, we identified 3658 HD patients with statin therapy for HL as the statin cohort, and then selected, by 1:1 propensity score matching, 3658 HD patients with HL but without statin use as the nonstatin cohort in 2000-07. The cohorts were followed through until the end of 2011. We used Cox proportional hazards regression analysis to assess the hazard ratio (HR) of PAD development. RESULTS: The average follow-up period was 4.18 years; the incident PAD risk was 1.35-fold greater in statin users than in nonusers (16.87 versus 12.46/1000 person-years), with an adjusted HR (aHR) of 1.34 for PAD [95% confidence interval (CI) 1.12-1.62]. The PAD risk increases were significant for patients receiving fluvastatin (aHR 1.88; 95% CI 1.12-3.14) and atorvastatin (aHR 1.60; 95% CI 1.24-2.08). The risk increased with higher annual average statin dosage (P for trend <0.0001); the risk was higher for those receiving moderate-intensity statin treatment. The sensitivity test revealed similar findings. CONCLUSIONS: HD patients with HL on statin medication were at increased PAD risk, which increased with cumulative statin dosage. Thorough considerations are needed before prescribing statins to HD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hsu YH, Sung FC, Muo CH, et al. Increased risk of developing peripheral artery disease in hemodialysis patients receiving statin treatments: a population-based cohort study in Taiwan. Nephrol Dial Transplant. 2020. PMID: 31821490. doi:10.1093/ndt/gfz251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。